The growth in the historic period can be attributed to growth in chemotherapy treatment volumes, adoption of colony-stimulating factors, improvements in oncology supportive care standards, increasing hospital-based cancer care, rising awareness of neutropenia risks.
The growth in the forecast period can be attributed to expansion of long-acting biologic drug pipelines, rising demand for outpatient cancer care support, growth of personalized oncology treatment regimens, increasing focus on reducing hospitalization rates, supportive reimbursement for oncology biologics. Major trends in the forecast period include increasing use of long-acting g-csf therapies, rising focus on chemotherapy supportive care, expansion of infection risk reduction protocols, improved oncology treatment outcomes, enhanced patient convenience and compliance.
The increasing prevalence of cancer is expected to drive growth in the Ryzneuta market going forward. Cancer is a group of diseases characterized by the uncontrolled growth of abnormal cells, which can form tumors, invade nearby tissues, and spread to other parts of the body via the bloodstream or lymphatic system. Factors contributing to the rising prevalence of cancer include aging populations, unhealthy lifestyle choices, environmental exposures, genetic predispositions, improved detection methods, and chronic inflammation or infections. Ryzneuta helps manage cancer by targeting and inhibiting specific mechanisms of cancer cell growth, enhancing the immune response, and improving treatment outcomes for certain cancers, such as non-Hodgkin lymphoma. For example, in February 2024, the World Health Organization (WHO) projected that annual new cancer cases will increase from approximately 20 million in 2022 to over 35 million by 2050, representing a 77% growth over the period. Therefore, the rising prevalence of cancer is driving growth in the Ryzneuta market.
Key companies in the Ryzneuta market are focusing on innovative drug development, such as efbemalenograstim alfa injections, to address unmet medical needs, enhance treatment efficacy, and improve patient outcomes. Efbemalenograstim alfa is a long-acting granulocyte colony-stimulating factor (G-CSF) that reduces the duration of neutropenia and the incidence of febrile neutropenia in patients undergoing chemotherapy. For instance, in November 2024, Evive Biotech Private Limited, a Singapore-based biopharmaceutical company, partnered with Acrotech Biopharma LLC, a US-based pharmaceutical company, to launch Ryzneuta in Germany. This biologic treatment stimulates white blood cell production, helping reduce infection risk in patients undergoing chemotherapy or other treatments that suppress immune function, thereby improving recovery and patient outcomes.
In November 2023, Acrotech Biopharma LLC partnered with Evive Biotech Private Limited to commercialize Ryzneuta (Efbemalenograstim alfa) in the United States. Under this collaboration, Evive Biotech granted Acrotech exclusive rights to market and distribute the drug in the US, strengthening both companies’ presence in the oncology therapeutics market. Evive Biotech focuses on developing a portfolio of novel biological therapies, while Acrotech specializes in the commercialization of innovative proprietary medications.
Major companies operating in the ryzneuta market are Evive Biotech Private Limited, Acrotech Biopharma LLC.
North America was the largest region in the ryzneuta market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ryzneuta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ryzneuta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the ryzneuta market by increasing costs of imported biologic manufacturing inputs, formulation equipment, prefilled syringe components, and temperature-controlled logistics. Oncology treatment centers in North America and Europe are most affected due to reliance on imported biologics, while other regions face access and pricing challenges. These tariffs are increasing overall therapy costs and procurement complexity. However, they are also encouraging domestic biologics manufacturing, localized fill-and-finish operations, and greater investment in regional oncology drug supply chains.
The ryzneuta market research report is one of a series of new reports that provides ryzneuta market statistics, including ryzneuta industry global market size, regional shares, competitors with a ryzneuta market share, detailed ryzneuta market segments, market trends and opportunities, and any further data you may need to thrive in the ryzneuta industry. This ryzneuta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Ryzneuta (efbemalenograstim alfa) is a long-acting granulocyte colony-stimulating factor (G-CSF) used to lower the risk of infection in adults with non-myeloid cancers undergoing chemotherapy. It works by stimulating the production of neutrophils, a type of white blood cell essential for fighting infections.
The primary indications for Ryzneuta include chemotherapy-induced neutropenia, cyclic neutropenia, idiopathic neutropenia, and congenital neutropenia. Chemotherapy-induced neutropenia occurs when chemotherapy lowers neutrophil levels, increasing the risk of severe, potentially life-threatening infections due to weakened immunity. Ryzneuta is available in parenteral and oral formulations and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It serves end users including hospitals, specialty clinics, home healthcare, and research and academic institutions.
The ryzneuta market consists of sales of injectable formulations, combination therapies, pre-filled syringes, autoinjectors, and biosimilar alternatives. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to expansion of long-acting biologic drug pipelines, rising demand for outpatient cancer care support, growth of personalized oncology treatment regimens, increasing focus on reducing hospitalization rates, supportive reimbursement for oncology biologics. Major trends in the forecast period include increasing use of long-acting g-csf therapies, rising focus on chemotherapy supportive care, expansion of infection risk reduction protocols, improved oncology treatment outcomes, enhanced patient convenience and compliance.
The increasing prevalence of cancer is expected to drive growth in the Ryzneuta market going forward. Cancer is a group of diseases characterized by the uncontrolled growth of abnormal cells, which can form tumors, invade nearby tissues, and spread to other parts of the body via the bloodstream or lymphatic system. Factors contributing to the rising prevalence of cancer include aging populations, unhealthy lifestyle choices, environmental exposures, genetic predispositions, improved detection methods, and chronic inflammation or infections. Ryzneuta helps manage cancer by targeting and inhibiting specific mechanisms of cancer cell growth, enhancing the immune response, and improving treatment outcomes for certain cancers, such as non-Hodgkin lymphoma. For example, in February 2024, the World Health Organization (WHO) projected that annual new cancer cases will increase from approximately 20 million in 2022 to over 35 million by 2050, representing a 77% growth over the period. Therefore, the rising prevalence of cancer is driving growth in the Ryzneuta market.
Key companies in the Ryzneuta market are focusing on innovative drug development, such as efbemalenograstim alfa injections, to address unmet medical needs, enhance treatment efficacy, and improve patient outcomes. Efbemalenograstim alfa is a long-acting granulocyte colony-stimulating factor (G-CSF) that reduces the duration of neutropenia and the incidence of febrile neutropenia in patients undergoing chemotherapy. For instance, in November 2024, Evive Biotech Private Limited, a Singapore-based biopharmaceutical company, partnered with Acrotech Biopharma LLC, a US-based pharmaceutical company, to launch Ryzneuta in Germany. This biologic treatment stimulates white blood cell production, helping reduce infection risk in patients undergoing chemotherapy or other treatments that suppress immune function, thereby improving recovery and patient outcomes.
In November 2023, Acrotech Biopharma LLC partnered with Evive Biotech Private Limited to commercialize Ryzneuta (Efbemalenograstim alfa) in the United States. Under this collaboration, Evive Biotech granted Acrotech exclusive rights to market and distribute the drug in the US, strengthening both companies’ presence in the oncology therapeutics market. Evive Biotech focuses on developing a portfolio of novel biological therapies, while Acrotech specializes in the commercialization of innovative proprietary medications.
Major companies operating in the ryzneuta market are Evive Biotech Private Limited, Acrotech Biopharma LLC.
North America was the largest region in the ryzneuta market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ryzneuta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ryzneuta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the ryzneuta market by increasing costs of imported biologic manufacturing inputs, formulation equipment, prefilled syringe components, and temperature-controlled logistics. Oncology treatment centers in North America and Europe are most affected due to reliance on imported biologics, while other regions face access and pricing challenges. These tariffs are increasing overall therapy costs and procurement complexity. However, they are also encouraging domestic biologics manufacturing, localized fill-and-finish operations, and greater investment in regional oncology drug supply chains.
The ryzneuta market research report is one of a series of new reports that provides ryzneuta market statistics, including ryzneuta industry global market size, regional shares, competitors with a ryzneuta market share, detailed ryzneuta market segments, market trends and opportunities, and any further data you may need to thrive in the ryzneuta industry. This ryzneuta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Ryzneuta (efbemalenograstim alfa) is a long-acting granulocyte colony-stimulating factor (G-CSF) used to lower the risk of infection in adults with non-myeloid cancers undergoing chemotherapy. It works by stimulating the production of neutrophils, a type of white blood cell essential for fighting infections.
The primary indications for Ryzneuta include chemotherapy-induced neutropenia, cyclic neutropenia, idiopathic neutropenia, and congenital neutropenia. Chemotherapy-induced neutropenia occurs when chemotherapy lowers neutrophil levels, increasing the risk of severe, potentially life-threatening infections due to weakened immunity. Ryzneuta is available in parenteral and oral formulations and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It serves end users including hospitals, specialty clinics, home healthcare, and research and academic institutions.
The ryzneuta market consists of sales of injectable formulations, combination therapies, pre-filled syringes, autoinjectors, and biosimilar alternatives. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Ryzneuta Market Characteristics
3. Ryzneuta Market Supply Chain Analysis
4. Global Ryzneuta Market Trends and Strategies
5. Ryzneuta Market Analysis of End Use Industries
7. Global Ryzneuta Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Ryzneuta Total Addressable Market (TAM) Analysis for the Market
9. Ryzneuta Market Segmentation
10. Ryzneuta Market Regional and Country Analysis
11. Asia-Pacific Ryzneuta Market
12. China Ryzneuta Market
13. India Ryzneuta Market
14. Japan Ryzneuta Market
15. Australia Ryzneuta Market
16. South Korea Ryzneuta Market
17. Western Europe Ryzneuta Market
18. UK Ryzneuta Market
19. Germany Ryzneuta Market
20. France Ryzneuta Market
21. Eastern Europe Ryzneuta Market
22. North America Ryzneuta Market
23. USA Ryzneuta Market
24. Canada Ryzneuta Market
25. South America Ryzneuta Market
26. Middle East Ryzneuta Market
27. Africa Ryzneuta Market
29. Ryzneuta Market Competitive Landscape and Company Profiles
32. Ryzneuta Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Ryzneuta Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses ryzneuta market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for ryzneuta? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ryzneuta market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indication: Chemotherapy-Induced Neutropenia; Cyclic Neutropenia; Idiopathic Neutropenia; Congenital Neutropenia2) By Route Of Administration: Parenteral; Oral
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End User: Hospitals; Specialty Clinics; Home Healthcare; Research And Academic Institutes
Companies Mentioned: Evive Biotech Private Limited; Acrotech Biopharma LLC
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Ryzneuta market report include:- Evive Biotech Private Limited
- Acrotech Biopharma LLC
